CalciMedica
LA JOLLA, CA · Biotechnology, Healthcare · 16 employees
CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambrid
Funding history
- Series A — $1.2M — Jul 2026
- Debt Financing — $32.5M — Mar 2025
- Venture - Series Unknown — $9.1M — Apr 2023
- Venture - Series Unknown — $10.3M — Apr 2023
- Venture - Series Unknown — $17.2M — May 2020
Recent signals
- Jul 03, 2026: Raised $1.2M in Series A
- Jan 28, 2026: SEC 8-K (7.01): On January 28, 2026, CalciMedica, Inc. announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora TM in patients suffering from Stage 2 or Stage 3 acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF). This decision was made following a recommendation from the trial's Independent Data Monitoring Committee (IDMC). The trial discontinuation may have significant implications for the company's strategy and future development plans regarding Auxora TM, particularly in the context of treating AKI and AHRF patients. A copy of the press release detailing this decision is attached as Exhibit 99.1.
- Mar 05, 2025: Raised $32.5M in Debt Financing
- Nov 07, 2024: CalciMedica Appoints Stephen Bardin as Chief Financial Officer
- Apr 04, 2023: Raised $9.1M in Venture - Series Unknown
- Apr 04, 2023: Raised $10.3M in Venture - Series Unknown
- May 27, 2020: Raised $17.2M in Venture - Series Unknown
- Aug 15, 2019: Raised $55.0M in Venture - Series Unknown
See plans & pricing → Track CalciMedica’s funding, hiring, and signals — with verified contacts — on Fundz.